NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE: BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/bellring-brands-inc-class-action-lawsuit.

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Replimune, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/replimune-group-class-action-lawsuit.

Palo Alto Networks is acquiring Israeli identity security provider CyberArk in a deal valued at roughly $25 billion. The California-based cybersecurity company will pay $45 a share for CyberArk

NEM trims Q2 AISC by 4%, but rising capital spending may challenge its cost edge in the coming quarters.

ARMN's Q1 gold sales rose 6% Y/Y, fueling record revenues and a 137% surge in earnings from mine operations.

United Therapeutics (UTHR) came out with quarterly earnings of $6.41 per share, missing the Zacks Consensus Estimate of $6.8 per share. This compares to earnings of $5.85 per share a year ago.

– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.“ Such grant should solidify the Company's European Union exclusivity of Annamycin, also known by its non-proprietary name of naxtarubicin, with the potential to become the first non-cardiotoxic anthracycline.

SAN MATEO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- This month, Amazon and Whole Foods Market released their annual sustainability and impact reports, providing an in-depth look at their ongoing commitment and efforts to nourish people and the planet. In both reports, Windfall Bio was recognized for its nature-based solution harnessing mems to transform methane into high-value organic fertilizer. Mems are natural soil microbes that consume methane directly from a variety of gas streams. This approach enables customers from various industries to operate more efficiently and profitably, while also reducing their overall carbon footprint, as methane has over 86x greater …

New York, United States, July 30, 2025 (GLOBE NEWSWIRE) -- Graphjet Technology (“Graphjet” or “the Company”) is pleased to announce the successful arrival of its new machineries and equipment to its factory in Malaysia today, as planned.

Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset

Danone S.A. (OTCQX:DANOY) H1 2025 Earnings Call July 30, 2025 5:30 AM ET Company Participants Georges Bahjat Elhedery - CEO, Member of the Group Management Board & Executive Director Manveen Pam Kaur - Group CFO & Executive Director Conference Call Participants Amandeep Singh Rakkar - Barclays Bank PLC, Research Division Benjamin Toms - RBC Capital Markets, Research Division Gurpreet Singh Sahi - Goldman Sachs Group, Inc., Research Division Jiahui Yan - China International Capital Corporation Limited, Research Division Joseph Dickerson - Jefferies LLC, Research Division Katherine L.

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1 per share a year ago.

EXL is a premium Genesys AppFoundry partner, bringing advanced data, AI, and domain expertise to the experience orchestration engine EXL is a premium Genesys AppFoundry partner, bringing advanced data, AI, and domain expertise to the experience orchestration engine

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met1 The safety profile in …

NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.

NEW YORK--(BUSINESS WIRE)--Pagaya Technologies Ltd. (“Pagaya” or the “Company”), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced that the Company's management team will participate in the following investor conferences: Bank of America's TMT Summer Fridays Fireside Chat Series Date: August 8, 2025 Location: Virtual Canaccord Growth Conference Date: August 12, 2025 Location: Boston, MA JP Morgan Future of Financials Forum Date: Augu.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union.